

Office of Regulatory Affairs (ORA)
Office of Medical Device and Radiological Health
2023 Update

OMDRHO PROGRAM

OMDRHO KEY INITIATIVES AND PRIORITIES

- RETURN TO INSPECTIONS
- COLLABORATION & OUTREACH

Anne Reid, OMDRHO Program Director

April 2023




PROGRAM

OMDRHO

OMDRHO | Office of Medical Device and Radiological Health Operations


ORA Organization Chart

THE FDA'S
OFFICE OF REGULATORY AFFAIRS (ORA) IS THE
LEAD OFFICE FOR ALL AGENCY FIELD ACTIVITIES.





Office of Medical Products and Tobacco Operations



OMDRHO

Office of Medical Device and Radiological Health Operations



Rhonda Mecl
Deputy Program Director



Anne Reid
Program Director

Shari Shambaugh
PDD Division 3

Blake Bevill
PDD Division 2

Joe Matrisciano
PDD Division 1

Akbar Zaidi
Foreign Staff Director





FY 23 Initiatives & Priorities

OMDRHO

Office of Medical Device & Radiological Health Operations (OMDRHO)

OMDRHO Vision: All patients, providers, and consumers are informed, protected, and have access to safe, reliable medical devices and radiological health products.

OMDRHO Mission: Protect and enhance public health by minimizing risk and by supporting access to safe, effective and quality medical devices and radiological health products.

FY 23 Key Priorities

All OMPTO Programs:

Enhance Investigator Preparedness

- OMDRHO -Decrease new staff time from on-boarding to operational thru training
 - Enhance mid-career experience with Peer Pro Groups
-

Optimize Inspectional Processes

- OMDRHO -Ensure global application of inspection priorities
 - Collaborate with CDRH on inspection considerations
-

Maximize our Tools for Regulatory Oversight

- OMDRHO -Collaborate with CDRH on Recall Process Improvement
 - Improve use and enforcement of UDI
 - Join CDRH in one device oversight and total product lifecycle & Quality Compliance Action Team
 - Expand program outreach
-

FY23 OMDRHO Key Initiatives


WORKFORCE	<ul style="list-style-type: none">- Inspectional guidance when encounter 510k concerns- EUA resource summary for investigators	
RISK MANAGEMENT	<ul style="list-style-type: none">- Review post market signals by firm for follow-up needs- RRA Process Improvements	
PARTNERSHIPS	<ul style="list-style-type: none">- PEAC- MedCon- OMDHRO Conference -Supply chain/shortages	
STRATEGIC DIRECTION	<ul style="list-style-type: none">- One Medical Device and Radiological Health Program- 820 Transition	

Remote Regulatory Assessments

(RRA)

- Multi-Commodity- will continue to see use of this regulatory tool
- Remote, interactive engagement to review records firms are required to maintain
- Voluntary-no Form 483 Inspectional Observations
- Devices transitioning from voluntary to utilizing new authority






Return to Inspections


OMDRHO

Inspections by FY




Inspections, FY17 - 22

FY23 YTD



on pace for FY19 numbers


FY17 – FY22



Inspection Classifications


PAST 10 YEARS

■ NAI ■ VAI ■ OAI




FY17 - FY23


■ NAI ■ VAI ■ OAI



Recall Events by FY




Recall Events Classification



Warning Letters by FY

Warning Letters by Fiscal Year

Fiscal Years: 2017, 2018, 2019, 2020, 2021, 2022





COLLABORATION

OMDRHO, CDRH, Industry &
Academia

Stakeholder Outreach

- Education
- OMDRHO Conference
- Industry Talks & MedCon Tradition
 - **Upcoming ORA Talks:**
 - **Day 1**
 - Are You Assuring All Your Suppliers Are Meeting Purchasing Controls Requirements
 - The Do's and Don'ts of 483 and Warning Letter Responses
 - **Day 2**
 - Update on Proposed Rule Aligning QSR With 13485 (QMSR)
 - Demonstration on FDA Databases and Publicly Available Tools
 - **Day 3**
 - Investigator Insights
 - Understand the Recalls Process from Initiation to Termination!

OMDRHO webpage on fda.gov



www.fda.gov/ORADevices

Office of Medical Device and Radiological Health Operations (OMDRHO)

[Share](#) [Tweet](#) [LinkedIn](#) [Email](#) [Print](#)

Office of Medical Device and Radiological Health Operations (OMDRHO)

[A Day in the Life - Medical Device Program](#)

[Frequently Asked Questions About FDA Inspections of Combination Products](#)

[OMDRHO 2022 Annual Virtual Conference - 07/13/2022](#)

[Working Together - Keeping Informed: FDA Medical Device Virtual Conference 2021 -](#)

What We Do




- [Inspections](#)
- [Remote Regulatory Assessments \(RRA\)](#)
- [Recalls](#)
- [Compliance](#)
- [Medical Device Databases](#)
- [CDRH Related Links](#)
- [Additional Information](#)

Content current as of: 02/22/2022

Regulated Product(s)
Medical Devices
Radiation-Emitting Products

Strategic work with CDRH

FDA



Medical Device and Radiological Health Quality and Compliance Program Vision Statement

To collaboratively advance and continuously improve the quality, safety, and effectiveness of medical devices and radiological health products to meet patient needs.

One Medical Device Program Themes

- 1 Advance stakeholder access to modern technology, innovative products, and science based information

- 2 Ensure patient and consumer health by promptly, efficiently, and strategically addressing product safety issues

- 3 Foster product excellence and manufacturing innovation to improve product safety, effectiveness, and availability

- 4 Cultivate a culture of workforce excellence, innovation, and continuous improvement to advance regulatory science and improve public health

CDRH & ORA Program/Initiatives (some)



[FDA's Remote Oversight Tools | FDA](#)

[Patient Engagement Advisory Committee | FDA](#)

[How to Study and Market Your Device | FDA](#)

[Total Product Life Cycle Advisory Program \(TAP\) | FDA](#)

[Collaborative Communities: Addressing Health Care Challenges Together | FDA](#)

[CDRH Strategic Priorities and Updates | FDA](#)

[Conducting Remote Regulatory Assessments Questions and Answers | FDA](#)

[Case for Quality | FDA](#)

Updated Compliance Program 7382.845





Questions?

Disclaimer

These PowerPoint slides are the intellectual property of the U.S. Food and Drug Administration and the individual presenter and are protected under copyright Laws of the United States of America and other countries.
All rights reserved.



U.S. FOOD & DRUG
ADMINISTRATION

Thank You!